63843-83-4

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzyl-4-phenylpiperidin-4-ol is used as a potential analgesic agent for its pain-relieving properties, which are suggested to be similar to those of pethidine. It is being studied for its efficacy in managing various types of pain, although more research is needed to confirm its safety and effectiveness.
Used in Research and Development:
BPPO serves as a valuable compound in scientific research, particularly in the field of pharmacology, where it is used to study the mechanisms of action and potential therapeutic applications of opioid-like substances. Its structural differences from pethidine provide a basis for understanding the role of specific molecular features in the activity of analgesic drugs.
Used in Drug Abuse and Dependence Studies:
Due to its potential for abuse and dependence, 1-Benzyl-4-phenylpiperidin-4-ol is utilized in research aimed at understanding the factors contributing to substance abuse and developing strategies for prevention and treatment. This includes studying its addictive properties and comparing them with other opioids to inform the development of safer and less addictive pain management therapies.

InChI:InChI=1/C18H21NO/c20-18(17-9-5-2-6-10-17)11-13-19(14-12-18)15-16-7-3-1-4-8-16/h1-10,20H,11-15H2

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 591-51-5 phenyllithium 
• 40807-61-2 4-hydroxy-4-phenylpiperidin 
• 100-44-7 benzyl chloride 
• 19798-90-4 3-benzyl-6-methyl-6-phenyl-[1,3]oxazinane 
• 50-00-0 formaldehyd 
• 934-53-2 cumenyl chloride 
• 100-46-9 benzylamine 
• 3287-99-8 benzylamine hydrochloride 
• 98-83-9 isopropenylbenzene 
• 5004-94-4 4-hydroxy-4-phenylpiperidine hydrochloride 
• 41979-39-9 4-piperidone hydrochloride 
• 100-39-0 benzyl bromide 
• 100-59-4 phenylmagnesium chloride 

Downstream Products

• 142001-85-2 4-Acetamido-4-phenyl-1-benzyl piperidine hydrochloride 
• 172733-78-7 N-(1-benzyl-4-phenylpiperidin-4-yl)acetamide 
• 400770-91-4 4‐fluoro‐4‐phenylpiperidine 
• 1274933-90-2 1-benzyl-4-fluoro-4-phenyl-piperidine 
• 43064-12-6 1,2,3,6-tetrahydro-4-phenylpyridine hydrochloride 
• 10272-49-8 4-phenylpiperidine hydrochloride 
• 94163-98-1 1-benzyl-4-phenyl-1,2,5,6-tetrahydropirydine hydrochloride 
• 181641-53-2 1-Benzyl-4-(formylamino)-4-phenylpiperidine 
• 38025-45-5 1-benzyl-4-phenyl-1,2,3,6-tetrahydro-pyridine 
• 40105-95-1 4,4-diphenyl-N-benzylpiperidine 
• 40807-61-2 4-hydroxy-4-phenylpiperidin 
• 94909-63-4 propionic acid-(1-benzyl-4-phenyl-[4]piperidyl ester) 
• 771-99-3 4-phenylpiperidine 
• 1333494-98-6 N-((S)-2-amino-3-((S)-1-((S)-1-((2S,3R)-4-(1-benzyl-4-phenylpiperidin-4-ylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-ylamino)-3-cyclohexyl-1-oxopropan-2-ylamino)-3-methyl-1-oxobutan-2-ylamino)-3-oxopropyl)-2,5-dihydroxybenzamide 

Relevant academic research and scientific papers

Shuttle arylation by Rh(I) catalyzed reversible carbon–carbon bond activation of unstrained alcohols

The advent of transfer hydrogenation and borrowing hydrogen reactions paved the way to manipulate simple alcohols in previously unthinkable manners and circumvented the need for hydrogen gas. Analogously, transfer hydrocarbylation could greatly increase the versatility of tertiary alcohols. However, this reaction remains unexplored because of the challenges associated with the catalytic cleavage of unactivated C–C bonds. Herein, we report a rhodium(I)-catalyzed shuttle arylation cleaving the C(sp2)–C(sp3) bond in unstrained triaryl alcohols via a redox-neutral β-carbon elimination mechanism. A selective transfer hydrocarbylation of substituted (hetero)aryl groups from tertiary alcohols to ketones was realized, employing benign alcohols as latent C-nucleophiles. All preliminary mechanistic experiments support a reversible β-carbon elimination/migratory insertion mechanism. In a broader context, this novel reactivity offers a new platform for the manipulation of tertiary alcohols in catalysis.

Synthetic method of 4 -phenyl piperidine hydrochloride

The invention discloses a synthesis method of 4 -phenylpiperidine hydrochloride, and the route is as shown in the specification. The method has the advantages of cheap and easily available raw materials, simple operation and post-treatment, high yield, high product purity and the like, and is suitable for industrial production.

CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS

The present invention provides cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications as described herein.

Synthesis and biological evaluation of picolinamides as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)

Synthesis of a series of 6-substituted picolinamide derivatives and their inhibitory activities against 11β-hydroxysteroid dehydrogenase type 1 are described. Optimization of the initial hit compound, N-cyclohexyl-6-(piperidin-1-yl)picolinamide (1) from high throughput screening of in-house library resulted in the discovery of the highly potent and metabolically stable compound 25, which was efficacious in a mouse ex vivo pharmacodynamic model and reduced the fasting blood glucose and insulin levels in a HF/STZ mouse model after oral dosing.

Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists

Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays a role in metabolic and CNS disorders. The modeling-supported design, synthesis and multi-parameter optimization (biological activity, solubility, metabolic stability, hERG) of novel quinazoline derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. Clusters of refined hMCHR1 homology models derived from the X-ray structure of the β2-adrenergic receptor, including extracellular loops, were developed and used to guide the design.

Synthesis and SAR study of 4-arylpiperidines and 4-aryl-1,2,3,6- tetrahydropyridines as 5-HT2C agonists

A series of substituted 4-arylpiperidines and a smaller family of 4-aryl-1,2,3,6-tetrahydropyridines were synthesized and their biological activity at the 5-HT2C receptor studied to determine whether either series showed noteworthy agonist activity. Structure-activity relationships were developed from the performed receptor binding assays and functional studies, and the results of the analysis are presented herein.

Structure-guided design and synthesis of P1′ position 1-phenylcycloalkylamine-derived pentapeptidic BACE1 inhibitors

Previously, we reported potent pentapeptidic BACE1 inhibitors with the hydroxymethylcarbonyl isostere as a substrate transition-state mimic. To improve the in vitro potency, we further reported pentapeptidic inhibitors with carboxylic acid bioisosteres at the P4 and P1′ positions. In the current study, we screened new P1′ position 1-phenylcycloalkylamine analogs to find non-acidic inhibitors that possess double-digit nanomolar range IC50 values. An extensive structure-activity relationship study was performed with various amine derivatives at the P1′ position. The most potent inhibitor of this pentapeptide series, KMI-1830, possessing 1-phenylcyclopentylamine at the P 1′ position had an IC50 value of 11.6 nM against BACE1 in vitro enzymatic assay.

(4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

New substituted isoquinoline and isoquinolinone derivatives

The invention relates to 6-substituted isoquinoline and isochinolone derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.

The design and discovery of novel amide CCR5 antagonists

The synthesis of a range of novel amine-containing structures and their primary potency as inhibitors of HIV-1 fusion via blocking of the CCR5 receptor is described. The development of the medicinal chemistry strategy and SAR's which led to the identification of the piperidine amide compounds 33 and 36 as excellent leads for further evaluation is described, along with key physicochemical data which highlighted their lead potential.